63 225

Cited 0 times in

Effects of Oral Pamidronate in Treatment of Primary Osteoporosis

Other Title
일차성 골다공증 환자에서 경구 파미드로네이트의 치료효과
Authors
고, 보람; 김, 형일; 김, 연경; 안, 상미; 송, 경은; 정, 선혜; 김, 혜진; 김, 대중; 이, 관우; 정, 윤석
Citation
Journal of Korean Society of Osteoporosis, 3(1):62-66, 2005
Journal Title
Journal of Korean Society of Osteoporosis; 대한골다공증학회지
ISSN
1738-0359
Abstract
Objectives: Bisphosphonates are well-known agents for treatment of osteoporosis. Oral pamidronate treatment for osteoporosis were studied in Caucasian, but not in Korean. Effects of oral pamidronate were studied in Korean primary osteoporosis patients. Methods: Twenty four(11 men and 13 women) primary osteoporosis patients were treated with 100mg of daily pamidronate(panorin, Hanlim Co., Korea) for mean duration of 13.5±1.9months. Serum alkaline phosphatase, urine calcium/ creatinine ratio, bone mineral densities of spine(L1-4) and femur(neck, trochanter, ward, and total) were followed-up. Results: Serum alkaline phsophatase decreased from 95.3±28.0 to 69.4±23.1IU/L(P<0.01). Urine calcium/creatinine ratio decreased from 0.132±0.076 to 0.083±0.052(P<0.05). Bone mineral density of spine increased from 0.788±0.137 to 0.841±0.144g/cm2(P<0.01). Bone mineral density of total proximal femur increased from 0.819±0.099 to 0.833±0.098g/cm2(P<0.05). Conclusion: Oral pamidronate treatment for 1 year was effective in increasing bone mineral density and decreasing biochemical bone turnover rate. Further study of prospective randomized double blind trial will be needed.
Keywords
Oral pamidronateOsteoporosisBone mineral density
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Endocrinology & Metabolism
Full Text Link
Files in This Item:
62-66.PDFDownload
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse